{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:04:48Z","timestamp":1793505888369,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ymgme.2023.107611","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T02:59:53Z","timestamp":1684465193000},"page":"107611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry"],"prefix":"10.1016","volume":"139","author":[{"given":"Lola E.R.","family":"Lessard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Tard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Salort-Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"B\u00e9hin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bassez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Orlikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Nollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gallay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Bouhour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lafor\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2023.107611_bb0005","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"Van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2023.107611_bb0010","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2023.107611_bb0015","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/ene.13285","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience","volume":"24","author":"Van der Ploeg","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107611_bb0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.neurol.2020.04.004","article-title":"Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network","volume":"176","author":"Sol\u00e9","year":"2020","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.ymgme.2023.107611_bb0025","author":"EMA (European Medicines Agency)"},{"key":"10.1016\/j.ymgme.2023.107611_bb0030","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of Alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"Van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2023.107611_bb0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/gim.2016.70","article-title":"Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy","volume":"19","author":"De Vries","year":"2017","journal-title":"Genet Med."},{"key":"10.1016\/j.ymgme.2023.107611_bb0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2023.107611_bb0045","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2023.107611_bb0050","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International consensus on drug allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy."},{"key":"10.1016\/j.ymgme.2023.107611_bb0055","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/ijms18061316","article-title":"Drug hypersensitivity and Desensitizations: mechanisms and new approaches","volume":"18","author":"De las Vecillas S\u00e1nchez","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2023.107611_bb0060","first-page":"1006","article-title":"Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European academy of allergy and clinical immunology and the American Academy of allergy","volume":"72","author":"Muraro","year":"2017","journal-title":"Asthma Immunol.. Allerg."},{"key":"10.1016\/j.ymgme.2023.107611_bb0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","article-title":"Consensus treatment recommendations for late-onset Pompe disease: AAEM practice topic: late-onset Pompe disease","volume":"45","author":"Cupler","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2023.107611_bb0070","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(77)91953-5","article-title":"Incidence and severity of anaphylactoid reactions to colloid volume substitutes","volume":"309","author":"Ring","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2023.107611_bb0075","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/all.12437","article-title":"Anaphylaxis: guidelines from the European academy of allergy and clinical immunology","volume":"69","author":"Muraro","year":"2014","journal-title":"Allergy."},{"key":"10.1016\/j.ymgme.2023.107611_bb0080","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.nmd.2016.07.006","article-title":"SWORD: a simplified desensitization protocol for enzyme replacement therapy in adult Pompe disease","volume":"26","author":"Gallay","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2023.107611_bb0085","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1398-9995.2010.02441.x","article-title":"General considerations on rapid desensitization for drug hypersensitivity - a consensus statement: desensitization for drug hypersensitivity","volume":"65","author":"Cernadas","year":"2010","journal-title":"Allergy."},{"key":"10.1016\/j.ymgme.2023.107611_bb0090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2009.07.001","article-title":"Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa\u2606","volume":"98","author":"Lipinski","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107611_bb0095","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymgme.2011.07.004","article-title":"An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions","volume":"104","author":"El-Gharbawy","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107611_bb0100","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10545-018-0243-7","article-title":"Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study","volume":"41","author":"Semplicini","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.107611_bb0105","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1365-2125.2010.03774.x","article-title":"Epidemiology and risk factors for drug allergy: epidemiology and risk factors for drug allergy","volume":"71","author":"Thong","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2023.107611_bb0110","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jaip.2018.11.023","article-title":"Drug hypersensitivity reactions documented in electronic health records within a large health system","volume":"7","author":"Wong","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ymgme.2023.107611_bb0115","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1365-2222.2004.02070.x","article-title":"Self-reported drug allergy in a general adult Portuguese population","volume":"34","author":"Gomes","year":"2004","journal-title":"Clin. Htmlent Glyphamp. Asciiamp. Exp. Allerg."},{"key":"10.1016\/j.ymgme.2023.107611_bb0120","doi-asserted-by":"crossref","first-page":"276","DOI":"10.21037\/atm.2019.06.48","article-title":"Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease","volume":"7","author":"Alandy-dy","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymgme.2023.107611_bb0125","author":"Barbey"},{"key":"10.1016\/j.ymgme.2023.107611_bb0130","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","article-title":"A revised home treatment algorithm for Fabry disease: influence of antibody formation","volume":"108","author":"Smid","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107611_bb0135","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaip.2014.11.013","article-title":"Successful rapid desensitization to imiglucerase in an adult patient with Gaucher disease and documented IgE-mediated hypersensitivity","volume":"3","author":"Tsilochristou","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ymgme.2023.107611_bb0140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.anai.2020.08.026","article-title":"Successful desensitization of a patient with Fabry disease with agalsidase beta (Fabrazyme) anaphylaxis after omalizumab pretreatment","volume":"126","author":"DuBuske","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ymgme.2023.107611_bb0145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s13256-016-1060-y","article-title":"Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report","volume":"10","author":"Giuffrida","year":"2016","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.ymgme.2023.107611_bb0150","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/nan.12414","article-title":"Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD)","volume":"44","author":"Ripolone","year":"2018","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.ymgme.2023.107611_bb0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000453265","article-title":"Classification of drug hypersensitivity into allergic, p-i, and Pseudo-allergic forms","volume":"171","author":"Pichler","year":"2016","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.ymgme.2023.107611_bb0160","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy."},{"key":"10.1016\/j.ymgme.2023.107611_bb0165","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymgme.2023.107611_bb0170","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/ene.15222","article-title":"Motor and respiratory decline in patients with late onset Pompe disease after cessation of enzyme replacement therapy during COVID-19 pandemic","volume":"29","author":"Tard","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymgme.2023.107611_bb0175","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jaip.2015.11.012","article-title":"Diagnosis and management of infusion-related hypersensitivity reactions to enzyme replacement therapy for lysosomal diseases: the role of desensitization","volume":"4","author":"Aranda","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ymgme.2023.107611_bb0180","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.anai.2020.07.010","article-title":"Management of hypersensitivity reactions to enzyme replacement therapy in children with lysosomal storage diseases","volume":"125","author":"Turgay Yagmur","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ymgme.2023.107611_bb0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase a replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2023.107611_bb0190","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.ymgme.2023.107611_bb0195","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922300241X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922300241X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:54:54Z","timestamp":1761090894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671922300241X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S109671922300241X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107611","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107611"}}